loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Dipraglurant

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Dipraglurant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Addex's eyelid data fail to make clear case for spasm expansion
    Addex's eyelid data fail to make clear case for spasm expansion

    28 May 2022

    // N.P. Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/addexs-eyelid-data-fails-make-clear-case-spasm-expansion

    N.P. Taylor FIERCEBIOTECH
    28 May 2022
    Share Share
    Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Study
    Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Study

    26 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/27/2451728/0/en/Addex-Provides-Update-on-Dipraglurant-Blepharospasm-Phase-2-Feasibility-Clinical-Study.html

    GLOBENEWSWIRE
    26 May 2022
    Share Share
    Addex Therapeutics initiates phase 2b/3 study with dipraglurant for dyskinesia
    Addex Therapeutics initiates phase 2b/3 study with dipraglurant for dyskinesia

    02 Jul 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=139705&sid=2

    PHARMABIZ
    02 Jul 2021
    Share Share
    Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant
    Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant

    29 Jun 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/06/29/2254392/0/en/Addex-Therapeutics-Initiates-Pivotal-Phase-2b-3-Study-with-Dipraglurant-for-Dyskinesia-Associated-with-Parkinson-s-Disease.html

    GLOBENEWSWIRE
    29 Jun 2021
    Share Share